Nurix Therapeutics (NRIX) Common Equity (2019 - 2025)
Historic Common Equity for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $538.7 million.
- Nurix Therapeutics' Common Equity rose 223.04% to $538.7 million in Q4 2025 from the same period last year, while for Nov 2025 it was $538.7 million, marking a year-over-year increase of 223.04%. This contributed to the annual value of $538.7 million for FY2025, which is 223.04% up from last year.
- Nurix Therapeutics' Common Equity amounted to $538.7 million in Q4 2025, which was up 223.04% from $372.3 million recorded in Q3 2025.
- Nurix Therapeutics' 5-year Common Equity high stood at $538.7 million for Q4 2025, and its period low was $168.7 million during Q1 2024.
- Over the past 5 years, Nurix Therapeutics' median Common Equity value was $342.4 million (recorded in 2021), while the average stood at $342.8 million.
- As far as peak fluctuations go, Nurix Therapeutics' Common Equity plummeted by 3842.48% in 2024, and later surged by 18499.12% in 2025.
- Over the past 5 years, Nurix Therapeutics' Common Equity (Quarter) stood at $342.3 million in 2021, then decreased by 11.28% to $303.7 million in 2022, then tumbled by 33.98% to $200.5 million in 2023, then surged by 162.85% to $527.0 million in 2024, then increased by 2.23% to $538.7 million in 2025.
- Its last three reported values are $538.7 million in Q4 2025, $372.3 million for Q3 2025, and $447.6 million during Q2 2025.